PerAspera Holdings Ltd. (“PerAspera” or the “Company”) announces submission of licence applications to Health Canada for Adastra Labs and Chemia Analytics. “I am very proud of the team for being among the first in Canada, if not the first, to submit Standard Processing and Analytical Testing licence applications on the new CTLS rolled out by Health Canada just yesterday,” noted Andy Hale CEO of PerAspera.
Just 32 hours after the new Cannabis Tracking and Licensing System (CTLS) went live, both Adastra Labs and Chemia Analytics submitted their licence applications to Heath Canada. The CTLS is a web-based application and case management system, established and maintained by Health Canada, through which applicants may apply for a cannabis licence to be issued by Health Canada and through which monthly tracking requirements must be submitted. The CTLS went live Canada-wide on October 17th 2018.
“The CTLS upload and submission process for Adastra Labs’ Standard Processor licence was very straight-forward and intuitive. Clearly a lot of thought and testing went into development of the system by Health Canada to make for a smooth application process,” stated Donald Dinsmore, Quality Assurance Person for Adastra.
Sister company Chemia Analytics had a similar experience as noted by Head of Laboratory, Priyanka Nalawade, “I found the CTLS quite user-friendly. We hope our early submission will accelerate our licence application approval and look forward to working with Health Canada to facilitate this process.”
For further information, please contact:
Andy Hale, Chief Executive Officer
About PerAspera Holdings Ltd.
In Canada, PerAspera (through its wholly-owned subsidiaries, Adastra Labs Inc. and Chemia Analytics Inc.) is in the application process to become a Standard Processor under the Cannabis Act administered by Health Canada, with licences to produce cannabis extracts and provide third party analytical testing services. These licences will further enable PerAspera and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licenced entities and internationally in jurisdictions where medical cannabis extraction products are legal.
The Company’s operations includes a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing and laboratory testing by early 2019, from which it expects to produce significant amounts of cannabis oil for the Canadian wholesale medical and recreational markets.
The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, PerAspera will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.